Axonics, Inc. (AXNX)

NASDAQ: AXNX · IEX Real-Time Price · USD
49.94
0.63 (1.28%)
May 20, 2022 4:00 PM EDT - Market closed
Market Cap2.35B
Revenue (ttm)194.34M
Net Income (ttm)-80.23M
Shares Out47.07M
EPS (ttm)-1.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume414,345
Open50.56
Previous Close49.31
Day's Range47.72 - 50.94
52-Week Range38.41 - 79.81
Beta0.51
AnalystsBuy
Price Target72.55 (+45.3%)
Earnings DateMay 5, 2022

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and ...

IndustryHealth Care Equipment & Supplies
CEORaymond Cohen
Employees517
Stock ExchangeNASDAQ
Ticker SymbolAXNX
Full Company Profile

Financial Performance

In 2021, Axonics's revenue was $180.29 million, an increase of 61.64% compared to the previous year's $111.54 million. Losses were -$80.07 million, 45.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for AXNX stock is "Buy." The 12-month stock price forecast is 72.55, which is an increase of 45.27% from the latest price.

Price Target
$72.55
(45.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Axonics® Reports First Quarter 2022 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 weeks ago - Business Wire

Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out for

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Axonics® to Participate in BofA Securities 2022 Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

3 weeks ago - Business Wire

Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

1 month ago - Business Wire

Axonics® to Report First Quarter 2022 Financial Results on May 5

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

1 month ago - Business Wire

Axonics® Launches Direct to Consumer Television Advertising Campaign

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

1 month ago - Business Wire

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 months ago - Business Wire

Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 months ago - Business Wire

Earnings Preview: Axonics Modulation Technologies (AXNX) Q4 Earnings Expected to Decline

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

3 months ago - Business Wire

Axonics® to Participate in SVB Leerink Virtual Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

3 months ago - Business Wire

New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

3 months ago - Business Wire

Axonics (AXNX) Soars 7.4%: Is Further Upside Left in the Stock?

Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 months ago - Zacks Investment Research

Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

4 months ago - Business Wire

Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedic...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

5 months ago - Business Wire

Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

6 months ago - Business Wire

Deloitte Unveils 2021 North America Technology Fast 500 Rankings

SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Deloitte today released its "North America Technology Fast 500," an annual ranking of the fastest-growing North American companies in the technology, media, ...

6 months ago - PRNewsWire

Axonics® to Participate in Piper Sandler Virtual Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

6 months ago - Business Wire

Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 17.39% and -3.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Axonics® Reports Third Quarter 2021 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

6 months ago - Business Wire

Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

6 months ago - Business Wire

Axonics® to Report Third Quarter 2021 Financial Results on November 4

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

7 months ago - Business Wire

Axonics® Provides Additional Update on Inter Partes Review Proceedings

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

7 months ago - Business Wire